ATE478872T1 - Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung - Google Patents

Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung

Info

Publication number
ATE478872T1
ATE478872T1 AT02007163T AT02007163T ATE478872T1 AT E478872 T1 ATE478872 T1 AT E478872T1 AT 02007163 T AT02007163 T AT 02007163T AT 02007163 T AT02007163 T AT 02007163T AT E478872 T1 ATE478872 T1 AT E478872T1
Authority
AT
Austria
Prior art keywords
alkyl
group
cycloalkyl
optionally substituted
alkenyl
Prior art date
Application number
AT02007163T
Other languages
German (de)
English (en)
Inventor
Daniela Moravcova
Libor Havlicek
Vladimir Krystof
Rene Lenobel
Miroslav Strnad
Original Assignee
Ustav Ex Botan Av Cr V V I I O
Univerzita Palackeho V Olomouc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ustav Ex Botan Av Cr V V I I O, Univerzita Palackeho V Olomouc filed Critical Ustav Ex Botan Av Cr V V I I O
Application granted granted Critical
Publication of ATE478872T1 publication Critical patent/ATE478872T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
AT02007163T 2002-03-28 2002-03-28 Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung ATE478872T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02007163A EP1348707B1 (en) 2002-03-28 2002-03-28 Pyrazolo[4,3-d]pyrimidines, processes for their preparation and methods for therapy

Publications (1)

Publication Number Publication Date
ATE478872T1 true ATE478872T1 (de) 2010-09-15

Family

ID=27798825

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02007163T ATE478872T1 (de) 2002-03-28 2002-03-28 Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung

Country Status (9)

Country Link
US (1) US7745450B2 (enExample)
EP (1) EP1348707B1 (enExample)
JP (1) JP2005527565A (enExample)
AT (1) ATE478872T1 (enExample)
AU (1) AU2003226731B2 (enExample)
CA (1) CA2480409C (enExample)
DE (1) DE60237425D1 (enExample)
DK (1) DK1348707T3 (enExample)
WO (1) WO2003082872A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050154046A1 (en) * 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
KR100824193B1 (ko) * 2003-04-29 2008-04-21 화이자 인코포레이티드 고혈압 치료에 유용한5,7-디아미노피라졸로[4,3-ｄ]피리미딘
EP2256106B1 (en) * 2003-07-22 2015-05-06 Astex Therapeutics Limited 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
GB0327323D0 (en) * 2003-11-24 2003-12-31 Pfizer Ltd Novel pharmaceuticals
GB0327319D0 (en) * 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
JP2007517052A (ja) * 2003-12-23 2007-06-28 ノバルティス アクチエンゲゼルシャフト 二環式ヘテロ環式ｐ−３８キナーゼ阻害剤
JP2007532526A (ja) 2004-04-07 2007-11-15 ファイザー・インク ピラゾロ［４，３−ｄ］ピリミジン類
MEP8409A (en) * 2004-06-02 2011-12-20 Fused heterocyclic compound
JP5334414B2 (ja) 2004-09-06 2013-11-06 バイエル インテレクチュアル プロパティー ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規のピラゾロピリミジン
RU2425677C2 (ru) * 2005-01-21 2011-08-10 Астекс Терапьютикс Лимитед Соединения, предназначенные для использования в фармацевтике
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
PT1881985E (pt) * 2005-05-12 2011-02-01 Pfizer Formas cristalinas anidras de n-[1-(2-etoxietil)-5-(n- -etil-n-metilamino)-7-(4-metilpiridin-2-il-amino)-1h- -pirazolo[4,3-d]pirimidino-3-carbonil]metanossulfonamida
US7932257B2 (en) 2005-07-22 2011-04-26 Sunesis Pharmaceuticals, Inc. Substituted pyrazolo[4,3-d]pyrimidines as aurora kinase inhibitors
NL2000291C2 (nl) 2005-11-10 2009-02-17 Pfizer Prod Inc 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan.
FR2899107B1 (fr) * 2006-03-30 2008-06-13 Neurokin Entpr Unipersonnelle Utilisation de la (s)-roscovitine pour la fabrication d'un medicament
KR20090090336A (ko) 2006-12-12 2009-08-25 다케다 야쿠힌 고교 가부시키가이샤 융합된 헤테로시클릭 화합물
US20090099195A1 (en) * 2007-05-08 2009-04-16 Astrazeneca Ab Therapeutic Compounds 570
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
MX2011004680A (es) 2008-11-06 2011-05-25 Astrazeneca Ab Moduladores de beta amiloide.
CZ2009358A3 (cs) * 2009-06-03 2010-12-15 C3 Bio Gmbh 5,7-Disubstituované 3-isopropylpyrazolo[4,3-d]pyrimidiny pro použití jako lécivo a farmaceutické prípravky tyto látky obsahující
CZ302711B6 (cs) * 2009-06-03 2011-09-14 Univerzita Palackého v Olomouci Substituované deriváty 6-(2-hydroxybenzylamino)purinu, jejich použití jako léciva a farmaceutické prípravky tyto slouceniny obsahující
AU2012244550C1 (en) * 2011-04-21 2017-06-22 Origenis Gmbh Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors
WO2013014052A1 (en) 2011-07-22 2013-01-31 Glaxosmithkline Llc Composition
AR090650A1 (es) * 2012-04-12 2014-11-26 Alcon Res Ltd Tratamiento para respuestas inflamatorias inducidas por microbios en el ojo
US9173872B2 (en) 2012-08-24 2015-11-03 Glaxosmithkline Llc Pyrazolopyrimidine compounds
WO2014060112A1 (en) * 2012-10-19 2014-04-24 Origenis Gmbh Pyrazolo[4,3-d]pyrimidines as kinase inhibitors
SMT201700378T1 (it) 2012-11-20 2017-09-07 Glaxosmithkline Llc Nuovi composti
KR20150085081A (ko) 2012-11-20 2015-07-22 글락소스미스클라인 엘엘씨 신규 화합물
JP6216387B2 (ja) 2012-11-20 2017-10-18 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 新規化合物
CN103405439B (zh) * 2013-08-02 2014-12-31 上海市第十人民医院 嘧啶类化合物在制备真菌药物的应用
EP3271017A4 (en) * 2015-03-16 2018-11-14 Monash University Treatment of skin conditions
CZ307147B6 (cs) * 2015-05-14 2018-02-07 Ústav experimentální botaniky AV ČR, v. v. i. 5-Substituované 7-[4-(2-pyridyl)fenylmethylamino]-3-isopropylpyrazolo[4,3-d]pyrimidiny, jejich použití jako léčiva, a farmaceutické přípravky
CN109996546B (zh) 2016-09-30 2023-06-27 阿沙纳生物科学公司 P2x3和/或p2x2/3化合物及方法
CZ308484B6 (cs) * 2018-02-05 2020-09-16 Univerzita PalackĂ©ho v Olomouci 5-Alkylthio-7-[(4-arylbenzyl)amino]-1(2)H-pyrazolo[4,3-d]pyrimidiny pro léčení lymfomů
EP3797776B1 (en) * 2019-09-30 2025-07-23 Universitätsmedizin Mainz Cdk4/6 inhibitors for the treatment of psoriasis
WO2026123091A1 (pt) * 2024-12-12 2026-06-18 Centro Nacional De Pesquisa Em Energia E Materiais Compostos inibidores da adenosina quinase, composição farmacêutica e seus usos

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3988338A (en) * 1974-04-24 1976-10-26 Wisconsin Alumni Research Foundation 4-Substituted amino-2-substituted thio-pyrrolo-[2,3-d]pyrimidine derivatives
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
US5276143A (en) 1990-12-21 1994-01-04 E. I. Du Pont De Nemours And Company Dideoxyfructonucleosides and deoxyfructonucleotides
US5801015A (en) 1995-06-05 1998-09-01 Mitotix, Inc. Nucleic acid encoding a Candida cell cycle regulatory protein, TYP1 polypeptide
US6200980B1 (en) 1995-06-07 2001-03-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl purinone derivatives
DK0778277T3 (da) * 1995-12-08 2003-10-27 Pfizer Substituerede heterocycliske derivater som CRF antagonister
PL332040A1 (en) * 1996-08-28 1999-08-16 Pfizer Substitution 6,5-heterobicyclic derivatives
US5723608A (en) * 1996-12-31 1998-03-03 Neurogen Corporation 3-aryl substituted pyrazolo 4,3-d!pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands
CA2288910C (en) * 1997-04-25 2003-06-24 Pfizer Inc. Pyrazolopyrimidinones for sexual dysfunction
US5985848A (en) * 1997-10-14 1999-11-16 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of nucleoside metabolism
ES2203078T3 (es) * 1998-04-20 2004-04-01 Pfizer Inc. Parazolopirimidinonas inhibidoras de gmpc pde5 para el tratamiento de la disfuncion sexual.
ES2205945T3 (es) * 1998-10-23 2004-05-01 Pfizer Inc. Pirazolopirimidinonas inhibidoras de gmpc pde5 para el tratamiento de disfunciones sexuales.
WO2001019827A1 (en) * 1999-09-13 2001-03-22 Cipla Ltd. A novel process for the synthesis of sildenafil citrate
ES2272297T3 (es) * 1999-10-12 2007-05-01 Lilly Icos Llc Medicamento destinado al tratamiento de neuropatias.
DE10060388A1 (de) * 2000-12-05 2002-06-06 Merck Patent Gmbh Verwendung von Pyrazolo [4,3-d]pyrimidinen
BR0115995A (pt) * 2000-12-19 2004-01-13 Merck Patent Gmbh Formulação farmacêutica compreendendo pirazolo[4,3-d]pirimidinas e antitrombóticos, antagonistas de cálcio, prostaglandinas ou derivados de prostaglandina
GB0106661D0 (en) * 2001-03-16 2001-05-09 Pfizer Ltd Pharmaceutically active compounds
KR20040053210A (ko) * 2001-11-02 2004-06-23 화이자 프로덕츠 인크. Ｐｄｅ9 억제제를 사용한 인슐린 저항 증후군 및 2형당뇨병의 치료
US20030195205A1 (en) * 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders

Also Published As

Publication number Publication date
CA2480409A1 (en) 2003-10-09
EP1348707A1 (en) 2003-10-01
US20050080097A1 (en) 2005-04-14
AU2003226731A1 (en) 2003-10-13
AU2003226731B2 (en) 2008-05-22
JP2005527565A (ja) 2005-09-15
CA2480409C (en) 2010-06-22
WO2003082872A1 (en) 2003-10-09
DK1348707T3 (da) 2010-12-13
DE60237425D1 (de) 2010-10-07
US7745450B2 (en) 2010-06-29
EP1348707B1 (en) 2010-08-25

Similar Documents

Publication Publication Date Title
DE60237425D1 (de) PyrazoloÄ4,3-dÜpyrimidine, Verfahren zu ihrer Herstellung und therapeutische Anwendung
CA2184919A1 (en) New Piperazine Derivatives and Methods for the Preparation Thereof and Compositions Containing the Same
CA2337041A1 (en) Aminomethylcarboxylic acid derivatives
WO2003076458A3 (en) Selective dipeptide inhibitors of kallikrein
CA2368413A1 (en) Derivatives of pyrimido[6,1-a]isoquinolin-4-one
HUP0301671A2 (hu) 4-Fenil-piridin-származékok, mint neurokinin-1-receptor antagonisták, eljárás az előállításukra és alkalmazásuk
ATE225348T1 (de) Substituierte azaindolylidenderivate und verfahren zu ihrer herstellung
WO2005092858A3 (en) Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonist
SE0104332D0 (sv) Therapeutic agents
CA2534024A1 (en) Novel compounds having inhibitory activity against sodium-dependant transporter
MY141504A (en) Gamma secretase inhibitors
PT1159279E (pt) 4-oxo-4,7-di-hidrotieno¬2,3-b|piridino-5-carboxamidas como agentes antivirais
TW368501B (en) 7-(2-aminoethyl)-benzothiazolones
TW235297B (enExample)
JP2005538111A5 (enExample)
EP2289888A3 (en) Epoxycarboxylic acid amides, azides and amino alcohols and processes for preparation of alpha-keto amides by using them
CA2213080A1 (en) 1-aryl-2-acylamino-ethane compounds and their use as neurokinin especially neurokinin 1 antagonists
MY138051A (en) Compounds and processes
TW200420559A (en) Amine compounds and method for producing the same
AR023914A1 (es) Caprolactamas sustituidas, un proceso para su preparacion, composiciones farmaceuticas que las contienen, y su uso para la preparacion de composicionesfarmaceuticas en el tratamiento de tumores
EP0431520A3 (en) Heterocyclic acyl aminodiol beta-amino acid derivatives
DE50202381D1 (de) Geschützte tyrosinderivate, verfahren zu deren herstellung und deren verwendung zur herstellung von o-(2- ?18 f]-fluorethyl)-l-tyrosin
GB0113232D0 (en) Chemical process
MXPA01009768A (es) Analogos de fenoxazina utiles como inhibidores de la agregacion amiloide y para el tratamiento de la enfermedad de alzheimer y las enfermedades relacionadas con la amiloidosis.
RU2004114262A (ru) Нейротензии активные производные 2,3-диарилпиразолидина

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties